翰思艾泰-B(03378)12月15日至12月18日招股 预计12月23日上市

Core Viewpoint - The company, Hansai Aitai-B (03378), is set to launch an initial public offering (IPO) from December 15 to December 18, 2025, aiming to issue 18.321 million shares at a price range of HKD 28-32 per share, with trading expected to commence on December 23, 2025 [1] Company Overview - The company is a biotechnology firm specializing in structural biology, translational medicine, and clinical development, with a product pipeline that includes one core product and nine other candidates [1] - The core product, HX009, is a dual-function antibody fusion protein targeting PD-1 and SIRPα, currently undergoing multiple clinical trials in China [2] - The company also has two major products, HX301 and HX044, both in clinical stages focused on cancer treatment [3] Clinical Development - HX009 has completed Phase I clinical trials in Australia and China, with ongoing studies for advanced melanoma, Epstein Barr virus-positive non-Hodgkin lymphoma, and advanced cholangiocarcinoma [2] - HX301 is a multi-target kinase inhibitor with completed Phase I trials and is currently in a Phase II trial for glioblastoma in China [3] - HX044 is a novel dual-function antibody currently in I/IIa phase clinical trials for advanced solid tumors in Australia and China [3] Fundraising and Use of Proceeds - The company has entered cornerstone investment agreements with several investors, agreeing to subscribe for a total of 2.9178 million shares at the maximum price of HKD 32.00 per share [4] - The estimated net proceeds from the global offering, assuming a median price of HKD 30.00 per share, is approximately HKD 496 million, with allocations planned for R&D of core and major products, commercialization, and general corporate purposes [5]